Abstract
Acquired Immune Deficiency Syndrome is one of the world's serious health problems. Immune-based therapy is a new approach in the treatment of HIV infected patients. IMODTM with the ability to correct immune deficiencies has been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the possible side effects, evaluate its effect on CD4+ T Lymphocyte count and patients’ and physicians’ satisfactions for 600 HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events were not observed in any of IMODTM recipients. Therefore it was not needed to terminate the treatment in any of patient. The results of this study demonstrated that daily prescription of IMODTM significantly increases T Lymphocyte CD4+ and Total Lymphocyte Count in HIV-positive patients. In addition, nearly 90% of the patients and 70% physicians are satisfied by IMODTM treatment.
Keywords: Efficacy, IMODTM, post marketing surveillance, safety, satisfaction, side effect.
Infectious Disorders - Drug Targets
Title:Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS
Volume: 13 Issue: 1
Author(s): Minoo Mohraz, Abbas Sedaghat, SeyedAhmad SeyedAlinaghi, Hossein Asheri, Saeid Mohammaddoust, Farhad Gharibdoost, Hamid Reza Khorram Khorshid, Mohammad Farhadi, Seyed Hesamedin Madani and Koorosh Kamali
Affiliation:
Keywords: Efficacy, IMODTM, post marketing surveillance, safety, satisfaction, side effect.
Abstract: Acquired Immune Deficiency Syndrome is one of the world's serious health problems. Immune-based therapy is a new approach in the treatment of HIV infected patients. IMODTM with the ability to correct immune deficiencies has been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the possible side effects, evaluate its effect on CD4+ T Lymphocyte count and patients’ and physicians’ satisfactions for 600 HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events were not observed in any of IMODTM recipients. Therefore it was not needed to terminate the treatment in any of patient. The results of this study demonstrated that daily prescription of IMODTM significantly increases T Lymphocyte CD4+ and Total Lymphocyte Count in HIV-positive patients. In addition, nearly 90% of the patients and 70% physicians are satisfied by IMODTM treatment.
Export Options
About this article
Cite this article as:
Mohraz Minoo, Sedaghat Abbas, SeyedAlinaghi SeyedAhmad, Asheri Hossein, Mohammaddoust Saeid, Gharibdoost Farhad, Khorshid Khorram Hamid Reza, Farhadi Mohammad, Madani Hesamedin Seyed and Kamali Koorosh, Post Marketing Surveillance on Safety and Efficacy of IMOD in Iranian Patients with HIV/AIDS, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990031
DOI https://dx.doi.org/10.2174/18715265112129990031 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Islet Transplantation: Current Status and Future Direction
Micro and Nanosystems The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals Pharmaceutical Interventions for Frailty and Sarcopenia
Current Pharmaceutical Design Multiple Drugs Causing Severe Anemia in Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Kv1.3 Lymphocyte Potassium Channel Inhibition as a Potential Novel Therapeutic Target in Acute Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure
Current Stem Cell Research & Therapy Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Cardiovascular & Hematological Agents in Medicinal Chemistry Enteric Nervous System in Neonatal Necrotizing Enterocolitis
Current Pediatric Reviews Autologus Stem Cell Transplatation as a Care Option in Elderly Patients. A Review
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Monoclonal Antibodies: A Prospective and Retrospective View
Current Medicinal Chemistry Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Current Medicinal Chemistry Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Inflammatory Signaling Networks as Targets for Pharmacological Intervention of Chronic Diseases
Current Signal Transduction Therapy